At the American Society for Clinical Oncology meeting in Chicago this week, oncologists gathered at a panel on gene patenting to learn more about the subject and how it might affect their work. Session chair Kenneth Offit of the Memorial Sloan-Kettering Cancer Center asked the audience how many thought gene patenting should be stopped, and nearly everyone in the room raised their hands.